WGYRGFYC 

WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer[1].

DOTA-WC8 (39-625 nM) 在无细胞 SPR 实验中以纳摩尔级亲和力 (K_d=61.20 nM) 结合 HER2^[1]。
⁶⁸Ga]Ga-DOTA-WGYRGFYC (37 KBq；2 h) 可与 SKBR3 细胞中的 HER2 结合，其 IC₅₀为 51.89 nM^[1]。
10 μM Pyrotinib 处理可降低 SKBR3 细胞对 [⁶⁸Ga]Ga-DOTA-WGYRGFYC (37 KBq；15-120 min) 的摄取，表明 HER2 表达下调^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

[⁶⁸Ga]Ga-DOTA-WC8 (3.7 MBq；静脉注射；单剂量) 可在 HER2 阳性 SKBR3 肿瘤中特异性聚集，其肿瘤与肌肉的峰值比值为 4.31±0.32，并且能灵敏检测吡咯替尼治疗后 HER2 表达的降低情况^[1]。
[⁶⁸Ga]Ga-DOTA-WC8 (3.7 MBq；静脉注射；单剂量) 在 HER2 阴性的 MDA-MB-231 肿瘤中的摄取量极低，证实了其 HER2 特异性^[1]。
[⁶⁸Ga]Ga-DOTA-WC8 (静脉注射；单剂量) 在正常小鼠体内具有良好的药代动力学特征，表现为快速分布与清除^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1051.18

C₅₁H₆₂N₁₂O₁₁S

Trp-Gly-Tyr-Arg-Gly-Phe-Tyr-Cys

WGYRGFYC

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Guo X, et al. In Silico Design and Evaluation of Novel Peptide-Based PET Probe for Noninvasive Imaging of HER2 Expression in Breast Cancer. J Med Chem. 2025;68(10):10461-10472.  [Content Brief]